Brief: CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec
26/04/2025 21:12
April 26 (Reuters) - CG Oncology Inc CGON.O: CG ONCOLOGY ANNOUNCES BEST-IN-DISEASE DURABILITY DATA IN BOND-003 COHORT C AND PROMISING EARLY SIGNAL IN COHORT P FOR CRETOSTIMOGENE GRENADENOREPVEC AT THE AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING CG ONCOLOGY INC - CRETOSTIMOGENE MONOTHERAPY SHOWS 42.3% RESPONSE RATE AT 24 MONTHS CG ONCOLOGY INC - 58.3% PATIENTS SHOW DURABLE RESPONSE AT 24 MONTHS CG ONCOLOGY INC - 97.3% PATIENTS FREE FROM MIBC PROGRESSION AT 24 MONTHS CG ONCOLOGY INC - 91.6% RESPONDERS CYSTECTOMY-FREE AT 24 MONTHS CG ONCOLOGY INC - NO GRADE 3 OR GREATER ADVERSE EVENTS REPORTED Source text: ID:nGNX7DLCJh Further company coverage: CGON.O ((Reuters.Briefs@thomsonreuters.com;))